Argenx SE (NASDAQ:ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED).

The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for futility following its review of data from a pre-specified interim analysis.

Efgartigimod showed a favorable safety and tolerability profile, and no new safety signals were identified.

Also Read: Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

"We are disappointed the studies did not meet our desired outcome…," said Luc Truyen, Chief Medical Officer at argenx.

The IDMC conducted a futility evaluation of unblinded data from patients completing 24 weeks in the Phase 3 studies.

Following the closeout and database lock, ...